Geneva, 6 May 2020 – Italy has announced €120 million in new direct funding to Gavi, the Vaccine Alliance, to both support the vaccination of hundreds of millions of children against diseases like pneumonia, measles and polio as well as support universal access to a COVID-19 vaccine. The new pledge, made at the EU’s Coronavirus Global Response pledging conference, is an increase from their previous €100 million five-year direct pledge to Gavi for the 2016-2020 period.
“In these critical times, Italy confirms its strong commitment to global cooperation, effective multilateralism and global health,” said H.E. Ms. Emanuela Claudia Del Re, Vice-Minister of Foreign Affairs and International Cooperation of Italy. “Gavi is a key actor and a longstanding partner: we are proud to increase our direct contribution and ensure life-saving immunisation for an additional 300 million children as well as COVID-19 response. We need to ensure universal and equitable access to vaccines for everyone and leave no one behind.”
Italy has been a major donor to the Vaccine Alliance since 2006 when they became a founding member of IFFIm and is its third largest contributor with a total commitment of €492.3 million. Italy also took a leading role in launching the first Advance Market Commitment (AMC) to accelerate the development and availability of pneumococcal vaccines to children in the world’s poorest countries. They are the largest donor to the AMC having committed a total of US$ 635 million.
Gavi needs at least US$ 7.4 billion for the 2021-25 period to protect 300 million children in 68 lower-income countries against deadly diseases. This funding will also ensure that the immunisation systems needed to deliver a COVID-19 vaccine are sustained through the pandemic. Gavi’s replenishment will conclude at the Global Vaccine Summit, hosted by the UK government on 4 June.
“We are grateful to Italy for this absolutely vital funding, which will help us both vaccinate millions of the most vulnerable children as well as help us prepare for a potential roll-out of a COVID-19 vaccine to the most vulnerable,” said Dr Seth Berkley, CEO of Gavi, the Vaccine Alliance. “The development of a COVID-19 vaccine is our best chance of beating this disease, while we need to keep a hold on other diseases by ensuring vaccination continues. We cannot afford to have another epidemic, other diseases need to remain under control and the best tool we have is vaccination.”
Over 20 years, Gavi has helped to immunise more than 760 million children, saving more than 13 million lives. Over that time, the Alliance has also worked to strengthen health systems in the world’s poorest countries and establish vaccine stockpiles against serious global health security threats, including Ebola.
Testing positive for COVID-19 – even without symptoms – can be disruptive to daily life, but how long should we expect to test positive for?
First published on 29 October 2021, updated on 13 September 2022
The COVAX Facility is seeking expressions of interest from the subject matter experts to join the COVAX Independent Product Group. The Independent Product Group (“IPG”) is established to provide scientific advice on COVID-19 vaccines and make…
Public speaking a lifelong skill for scientists. Drive behind research should come from grassroots. Science and art merge together in field of communication.
Kenya was aiming to reach 10 million people with COVID-19 vaccines by the end of December 2021. Thanks to a clear strategy, COVAX support and the hard work of thousands of health workers, they reached their target.
Moderna has begun a trial with an experimental HIV vaccine based on the same technology underpinning its COVID-19 vaccine.
Financial Times journalist and author Gillian Tett discusses her new book, Anthro-Vision: How Anthropology Can Explain Business and Life.
The COVID-19 pandemic has demonstrated the power of innovative Fourth Industrial Revolution (4IR) technologies in healthcare systems. Unless these technologies are designed with equity at their core, we risk leaving some people even further…
Faced with the many disease threats posed by repeated, calamitous floods, Nyando in western Kenya needs its health services more than ever. But longer-term resiliency will require more than just a shot in the arm.
Myocarditis following COVID-19 vaccination is rare, and the risk is much smaller than the risks of cardiac injury linked to COVID-19 itself.